<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209893">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355199</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT: 2005-00700-14</org_study_id>
    <nct_id>NCT00355199</nct_id>
  </id_info>
  <brief_title>Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.</brief_title>
  <official_title>Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Terapie Innovative nei Linfomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Terapie Innovative nei Linfomi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab
      followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high
      risk patients with DLBCL Non-Hodgkin's lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diffuse large B cells Non-Hodgkin's lymphomas represents one of the most frequent form of
      lymphoma. Its clinical development progresses rapidly and is characterized by a biphasic
      survival curve with patients in complete remission (which can be considered cured) and
      patients that relapse. This last group of subjects have only 25%-33% chance of long free
      disease survival if treated with a second line therapy with high dose chemotherapy plus
      autologous transplant of PBPC.

      Therefore in order to achieve an improvement of the overall survival in patient with DLBCL,
      it is necessary to increase the number of complete remission after first line therapy.

      The aim of R-HDS study, multicentre randomized phase III trial, is to evaluate and compare
      the efficacy and safety of an intensive conditioning regimen with high intensity
      chemo-immunotherapy (R-HDS) plus autologous transplantation versus CHOP conditioning regimen
      plus Rituximab in patients with unfavorable prognosis at diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>each 2 month during therapy administration and 1,3,6,9,12, 18, 24 months from end of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Remission</measure>
    <time_frame>each 2 month during therapy administration and 1,3,6,9,12, 18, 24 months from end of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>each 2 month during therapy administration and 1,3,6,9,12, 18, 24 months from end of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>each 2 month during therapy administration and 1,3,6,9,12, 18, 24 months from end of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>each 2 month during therapy administration and 1,3,6,9,12, 18, 24 months from end of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of R-HDS conditioning as salvage therapy in patients non-responders after four cycles of R-CHOP 14</measure>
    <time_frame>each 2 month during therapy administration and 1,3,6,9,12, 18, 24 months from end of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-HDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab-HDS</intervention_name>
    <description>Rituximab-HDS</description>
    <arm_group_label>R-HDS</arm_group_label>
    <other_name>Rituximab supplemented high-dose sequential chemotherapy.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab-CHOP</intervention_name>
    <description>Rituximab-CHOP</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Rituximab/Cyclophosph/doxorubic/vincrist/prednis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of DLBCL CD20+.

          -  Patients with Ann Arbor classification B-bulk &gt;= II

          -  Patients of age between 18-65 with age-adjusted IPI 2-3 and ECOG performance status
             0-3 or patients of age 61-65 with IPI 3, 4, 5 and ECOG performance status 0-2. The
             disease stage criteria must be documented with instrumental examinations and bone
             marrow biopsy.

          -  Hematology parameters one week before starting study as follows: Hb &gt;= 9 g/dl, WBC &gt;=
             3 x 10exp9/l, neutrophils &gt;= 1.5 x 10exp9/l, PLT &gt;= 100 x 10exp9/l.

          -  Patients with pulmonary DLCO &gt;= 50% and cardiac EF &gt;= 40%.

          -  Voluntary written informed consent must be signed before recruitment, with the
             understanding that consent may be withdrawn by the subject at any time without
             prejudice to future medical care. Patients must to be informed on the risk of
             sterility and they must agree to use contraception for the duration of the study.
             Male subject have to the opportunity of freezing seminal fluid.

        Exclusion Criteria:

          -  Diagnosis different from that describe above.

          -  Patients with concomitant, serious and uncontrolled illnesses such as cardiopathies
             (i.e. congestive cardiopathy, ischemic hearth disease, cardiac arrhythmia not
             controlled by therapy, IMA in the last six months, hearth disease NYHA class III or
             IV), hepatopathy not related to the lymphoma (bilirubin &gt;= 2 mg/dl, ALT &gt;= 2.5 times
             the normal value, alkaline phosphatase &gt;=2.5 times the upper limit), kidneys
             insufficiency not related to the lymphoma (creatinine &gt;=2 mg/dl).

          -  Patients affected by opportunistic infections or with positive serology for HIV, HCV,
             HbsAg (cases with normal levels of hepatic enzymes and not showing active viral
             replication documented with HBV-DNA are not excluded from randomization; patients
             with HBV+ can be enrolled after receiving prophylaxis with lamivudina one week before
             starting chemotherapy. These patients should be monitored twice a month for HbsAg,
             HBCab, HBV-DNA).

          -  Patients which have or have had another type of cancer exception made for skin
             cancers (melanoma and &quot;in situ&quot; cervical cancer not included).

          -  Patient with a history of anaphylaxes or more generally patients which have had any
             serious allergic reaction after serum infusion.

          -  Patient with uncontrolled epilepsy, CNS disorders or psychiatric problems which,
             according to the investigator, is likely to interfere with participation in this
             clinical study (i.e. the signing of the informed consent, therapy compliance).

          -  Inability to attend follow-up visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Cortelazzo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Divisione di Ematologia - Ospedale Centrale di Bolzano - 39100 Bolzano Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica di Ematologia - Nuovo Ospedale Torrette</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Ospedale Centrale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTMO - Ematologia - Ospedale &quot;R. Binaghi&quot;</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia - Istituto S. Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Azienda Ospedaliera</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Azienda Ospedaliera V. Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Clinica - Ospedale Civile di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e TMO - Ospedale S. Camillo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Universitaria di Ematologia - Azienda Ospedaliera S. Giovanni Battista (Molinette)</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica e Sperimentale - Universit√† di Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Presidio Ospedaliero S. Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>July 20, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>R-HDS</keyword>
  <keyword>R-CHOP14</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
